Volume 41, Number 2 (7-2017)                   Research in Medicine 2017, 41(2): 120-129 | Back to browse issues page


XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Mohammadzadeh M, Rasuli P, Ghari T. Trend analysis and future market forecasting of cardiovascular drugs in Iran . Research in Medicine. 2017; 41 (2) :120-129
URL: http://pejouhesh.sbmu.ac.ir/article-1-1620-en.html

Department of Pharmaceutics, School of pharmacy, Alborz University of Medical Sciences, Karaj, Iran / Pharmacoeconomy & Medical-Pharma Management Research Center, Tehran, Iran , tayebehghari@gmail.com
Abstract:   (286 Views)

Background and Aim: Variety in the pharmaceutical products and therapeutic groups, development of new pharmaceutical products and heavy costs in the pharmaceutical marketing, force the firms to attend in the specific area, related products and defined basket in order to decrease high marketing costs and act highly and accurately in the target market, costumer recognition and competitor analysis. To do this, market of cardiovascular disease as the most important parts of the pharmaceutical marketing has been evaluated during 15 years.

Materials and Methods: To do this, sale's statistics of 29 cardiovascular drugs were collected from official Iran drug list through 15 years. Then in order to forecast the consumption of each category, linear regression was used. A correlation between variables was tested by Pearson correlation coefficient.

Results: our results showed that Beta blockers and Nitrates from cardio drugs and Platelet aggregation inhibitors and Statins from vascular drugs have the highest consumption in comparison with other drugs. Also there is a positive correlation between total numbers of sales of cardio drugs, vascular drugs and cardiovascular drugs and middle age with correlation coefficients of 0.976, 0.979 and 0.976 and confidence interval of 95% and there is no correlation between the mentioned items and Gross domestic product. Cardiovascular drug consumption will increase by aging of the population. Gross domestic product will not affect the people payment’s ability

Conclusion: Based on our results, it is better for pharmaceutical companies to pay more attention to Beta blockers and Nitrates from cardio drugs and Platelet aggregation inhibitors and Statins from vascular drugs in order to decrease high marketing costs and act highly and accurately in the target market.

Full-Text [PDF 1308 kb]   (196 Downloads)    
Type of Study: Original | Subject: Cardiology
Received: 2016/07/4 | Accepted: 2017/05/15 | Published: 2017/08/9

Send email to the article author


Creative Commons License
This Journal is licensed under a Creative Commons Attribution 4.0 International License  | Research in Medicine

Designed & Developed by : Yektaweb